Literature DB >> 9538467

[Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus].

F Denis1, C C Adjide, S Rogez, C Delpeyroux, J P Rogez, P Weinbreck.   

Abstract

The serological status for both hepatitis B, C and D viruses was analyzed for 500 HIV seropositive patients and for 1037 of a control group. The prevalence was 31.4% for anti HCV, 13.8% for HBs Ag and 69.0% for one or more HBV markers in HIV positive patients and respectively 2.5%, 2.7% and 13.1% in control group. The markers for hepatitis D were founded among 21% of the HBs Ag carriers (patients and control group), correlated with drug i.v. use. The prevalence of anti-HCV was 71.6% in subjects who had blood-borne HIV infection and 1.5% in those with sexually acquired infection. The prevalence in control group was 10.2% and 1.7% respectively according to the same risk factors. The prevalence of HBs Ag was higher among HIV positive patients with sexual risk (17.5%) than with blood exposition (9.9%) and a variation in the same direction is observed in control group (3% v.s. 1%). The relation between markers for hepatitis B and hepatitis C was negative.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9538467

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  7 in total

1.  Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.

Authors:  Zobair M Younossi; Maria Stepanova; Mark Sulkowski; Susanna Naggie; Massimo Puoti; Chloe Orkin; Sharon L Hunt
Journal:  J Infect Dis       Date:  2015-01-12       Impact factor: 5.226

2.  Epidemiology of the viral hepatitis-HIV syndemic in San Francisco: a collaborative surveillance approach.

Authors:  Melissa A Sanchez; Susan Scheer; Sue Shallow; Sharon Pipkin; Sandra Huang
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

Review 3.  Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.

Authors:  Hsin-Yun Sun; Wang-Huei Sheng; Mao-Song Tsai; Kuan-Yeh Lee; Sui-Yuan Chang; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

4.  Prevalence and incidence of hepatitis B virus infection in STD clinic attendees in Pune, India.

Authors:  A Risbud; S Mehendale; S Basu; S Kulkarni; A Walimbe; V Arankalle; R Gangakhedkar; A Divekar; R Bollinger; D Gadkari; R Paranjape
Journal:  Sex Transm Infect       Date:  2002-06       Impact factor: 3.519

Review 5.  Therapeutic issues in HIV/HCV-coinfected patients.

Authors:  M S Sulkowski; Y Benhamou
Journal:  J Viral Hepat       Date:  2007-06       Impact factor: 3.728

6.  Social Determinants of HIV/HCV Co-Infection: A case Study from People Who Inject Drugs in Rural Puerto Rico.

Authors:  Roberto Abadie; Melissa Welch-Lazoritz; Khan Bilal; Kirk Dombrowski
Journal:  Addict Behav Rep       Date:  2017-01-30

7.  Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy.

Authors:  Tomokazu Mizui; Shunhei Yamashina; Isei Tanida; Yoshiyuki Takei; Takashi Ueno; Naoya Sakamoto; Kenichi Ikejima; Tsuneo Kitamura; Nobuyuki Enomoto; Tatsuo Sakai; Eiki Kominami; Sumio Watanabe
Journal:  J Gastroenterol       Date:  2009-09-17       Impact factor: 7.527

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.